Today’s announcement is in line with the latest press release relating to own production, dated March 29, 2019. This is an important milestone towards being able to produce uniform quality, which is the next milestone towards having self-produced medical cannabis products approved for the Danish medical cannabis Program.

STENOCARE’s indoor hygienic facility enables monitoring and control of all the vital parameters for growth of uniform and high-quality medical cannabis that complies with the strictest regulatory requirements. Now, a period of growing, harvesting, testing and adjusting the processes and equipment that enables consistent output quality from each batch will commence. STENOCARE will continue to leverage the know-how and technical assistance from its strategic partner, CannTrust Inc, during this period.

For additional information regarding STENOCARE, please contact:

Thomas Skovlund Schnegelsberg, CEO         
Phone: +45 31770060           
E-mail: presse@stenocare.com

This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person above for publication on June 25, 2019.

STENOCARE A/S (the Company) was founded in 2017 with the purpose of being an active participant in the Danish medical cannabis Program. The company was the first to receive the Danish Medicines Agency"s permission to import, distribute as well as cultivate and produce medical cannabis under the Program. The Company offers medical cannabis oils that comply with the strict Danish regulatory requirements and has developed a separate production facility for the cultivation and production of medical cannabis at the Company’s premises in Jutland, Denmark.